Novo Nordisk stock: does oral Wegovy approval make it better pick than Eli Lilly?

HSBC's senior research analyst Rajesh Kumar believes Novo Nordisk (NYSE: NVO) "might have an edge†over rival Eli Lilly (NYSE: LLY) heading into 2026. His remarks arrive shortly after the Danish pharm... ...